Holen Sie sich die Stockscreener-App
2.59
5.82%
-0.16
Handel nachbörslich:
2.60
0.01
+0.39%
Schlusskurs vom Vortag:
$2.75
Offen:
$2.76
24-Stunden-Volumen:
503.97K
Relative Volume:
1.12
Marktkapitalisierung:
$272.50M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-6.8374
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-9.44%
1M Leistung:
+5.71%
6M Leistung:
+30.15%
1J Leistung:
-30.56%
1-Tages-Spanne:
$2.48
$2.81
1-Wochen-Bereich:
$2.48
$3.00
52-Wochen-Spanne:
$1.07
$4.21
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.59 | 289.70M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases - TipRanks
Transcript : ProQR Therapeutics N.V.Shareholder/Analyst Call - MarketScreener
Can ProQR Therapeutics N.V. (0PQ) stock ride next bull market cycleJuly 2025 Price Swings & Reliable Momentum Entry Alerts - newser.com
Is ProQR Therapeutics N.V. stock a good choice for value investors2025 Short Interest & Daily Technical Stock Forecast Reports - newser.com
How ProQR Therapeutics N.V. (0PQ) stock compares with tech leadersJuly 2025 Selloffs & Verified Trade Idea Suggestions - newser.com
Why ProQR Therapeutics N.V. is moving todayJuly 2025 Gainers & Weekly Sector Rotation Insights - newser.com
Custom watchlist performance reports with ProQR Therapeutics N.V.Weekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
Does ProQR Therapeutics N.V. stock trade at a discount to peers - newser.com
Will ProQR Therapeutics N.V. stock outperform international peersWeekly Risk Summary & AI Powered Market Trend Analysis - newser.com
Will ProQR Therapeutics N.V. stock gain from government policiesMarket Volume Report & Stock Timing and Entry Methods - newser.com
Using Bollinger Bands to evaluate ProQR Therapeutics N.V.July 2025 Big Picture & Step-by-Step Swing Trade Plans - newser.com
Earnings visualization tools for ProQR Therapeutics N.V.2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 80.2% in October - Defense World
Is ProQR Therapeutics N.V. stock attractive for growth ETFsMarket Movers & Weekly Consistent Profit Watchlists - newser.com
Is ProQR Therapeutics N.V. stock cheap at current valuationJuly 2025 Momentum & Low Risk High Reward Trade Ideas - newser.com
Why analysts recommend ProQR Therapeutics N.V. (0PQ) stockQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
What catalysts could drive ProQR Therapeutics N.V. stock higherWeekly Loss Report & Consistent Return Strategy Ideas - newser.com
Key metrics from ProQR Therapeutics N.V.’s quarterly dataMarket Risk Summary & Safe Swing Trade Setup Alerts - newser.com
How sentiment analysis helps forecast ProQR Therapeutics N.V.2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Update - MarketBeat
What’s the recovery path for long term holders of ProQR Therapeutics N.V.July 2025 Snapshot & Daily Profit Focused Screening - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Visualizing ProQR Therapeutics N.V. stock with heatmapsTrade Entry Summary & Long Hold Capital Preservation Tips - newser.com
ProQR Therapeutics NV expected to post a loss of 10 cents a shareEarnings Preview - TradingView
ProQR Therapeutics (PRQR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Is ProQR Therapeutics N.V. (0PQ) stock at risk of policy regulation2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):